m8 Pharmaceuticals, a specialty biopharmaceutical company, has signed an exclusive licensing agreement with United Kingdom-based Pharmanovia for a portfolio of several brands for Mexico and Brazil, it was reported on Tuesday.

This portfolio includes established brands for the treatment of cardiovascular, nervous system, and rheumatological illnesses. The primary objective of the collaboration is to continue to strengthen the positioning of these products, offering continued support to physicians and ensuring access to patients in the territory.

The partnership is claimed to emphasise both firm's mutual focus to strengthen the presence of their medicines in Latin America, offering innovative and proven treatments with greater access to patients and caregivers throughout the region.